[1]
|
Patiño-Trives, A.M., Pérez-Sánchez, C., Pérez-Sánchez, L., et al. (2021) Anti-dsDNA Antibodies Increase the Cardio-vascular Risk in Systemic Lupus Erythematosus Promoting a Distinctive Immune and Vascular Activation. Arterioscle-rosis, Thrombosis, and Vascular Biology, 41, 2417-2430. https://doi.org/10.1161/ATVBAHA.121.315928
|
[2]
|
Gao, N., Kong, M., Li, X., et al. (2022) Systemic Lupus Er-ythematosus and Cardiovascular Disease: A Mendelian Randomization Study. Frontiers in Immunology, 13, Article ID: 908831. https://doi.org/10.3389/fimmu.2022.908831
|
[3]
|
Oliveira, C.B. and Kaplan, M.J. (2022) Cardiovascular Disease Risk and Pathogenesis in Systemic Lupus Erythematosus. Seminars in Immunopathology, 44, 309-324. https://doi.org/10.1007/s00281-022-00922-y
|
[4]
|
Frostegård, J. (2023) Systemic Lupus Erythematosus and Car-diovascular Disease. Journal of Internal Medicine, 293, 48-62. https://doi.org/10.1111/joim.13557
|
[5]
|
Radin, M., Cecchi, I., Roccatello, D., et al. (2018) Prevalence and Thrombotic Risk Assessment of Anti-β2 Glycoprotein I Domain I Antibodies: A Systematic Review. Seminars in Thrombosis and Hemostasis, 44, 466-474.
https://doi.org/10.1055/s-0037-1603936
|
[6]
|
Fierro, J.J., Velásquez, M., Cadavid, A.P., et al. (2022) Effects of Anti-Beta 2-Glycoprotein 1 Antibodies and Its Association with Pregnancy-Related Morbidity in Antiphospholipid Syn-drome. American Journal of Reproductive Immunology, 87, e13509. https://doi.org/10.1111/aji.13509
|
[7]
|
Cinoku, I.I., Mavragani, C.P. and Moutsopoulos, H.M. (2020) Atherosclerosis: Beyond the Lipid Storage Hypothesis. The Role of Autoimmunity. European Journal of Clinical Investigation, 50, e13195. https://doi.org/10.1111/eci.13195
|
[8]
|
Monjezi, M.R., Fouladseresht, H., Farjadian, S., et al. (2021) T Cell Prolif-erative Responses and IgG Antibodies to β2GPI in Patients with Diabetes and Atherosclerosis. Endocrine, Metabolic & Immune Disorders—Drug Targets, 21, 495-503. https://doi.org/10.2174/1871530320666200505115850
|
[9]
|
Kuang, W., Li, Y., Liu, G., et al. (2022) Correlation between Serum β2-GPI/oxLDL and the Risk of Cerebral Infarction in Patients with T2DM. Frontiers in Surgery, 9, Ar-ticle ID: 930701. https://doi.org/10.3389/fsurg.2022.930701
|
[10]
|
Sun, J., Lundström, S.L., Zhang, B., et al. (2018) IgM Antibodies against Phosphorylcholine Promote Polarization of T Regulatory Cells from Patients with Atherosclerot-ic Plaques, Systemic Lupus Erythematosus and Healthy Donors. Atherosclerosis, 268, 36-48. https://doi.org/10.1016/j.atherosclerosis.2017.11.010
|
[11]
|
王君君, 章帆, 姜丰, 等. 动脉粥样硬化指数与血清抗心磷脂抗体及抗β2糖蛋白1抗体水平的相关性研究[J]. 中国动脉硬化杂志, 2019, 27(7): 611-614.
|
[12]
|
赵维庆, 刘爽, 付李胤且, 等. 系统性红斑狼疮患者血清AECA检测临床意义的再评价[J]. 国际检验医学杂志, 2022, 43(2): 134-142.
|
[13]
|
Cieślik, P., Semik-Grabarczyk, E., Hrycek, A., et al. (2022) The Impact of Anti-Endothelial Cell Antibodies (AECAs) on the Development of Blood Vessel Damage in Patients with Systemic Lupus Erythematosus: The Preliminary Study. Rheumatology International, 42, 791-801. https://doi.org/10.1007/s00296-022-05104-5
|
[14]
|
高岭, 王莉, 殷丝雨, 等. 系统性红斑狼疮患儿血清抗内皮细胞抗体检测的临床意义[J]. 现代免疫学, 2021, 41(5): 392-396.
|
[15]
|
Morand, E.F., Furie, R., Tanaka, Y., et al. (2020) Trial of Anifrolumab in Active Systemic Lupus Ery-thematosus. The New England Journal of Medicine, 382, 211-221. https://doi.org/10.1056/NEJMoa1912196
|
[16]
|
Pattanaik, S.S., Panda, A.K., Pati, A., et al. (2022) Role of Interleu-kin-6 and Interferon-α in Systemic Lupus Erythematosus: A Case-Control Study and Meta-Analysis. Lupus, 31, 1094-1103.
https://doi.org/10.1177/09612033221102575
|
[17]
|
Lai, J.H., Hung, L.F., Huang, C.Y., et al. (2021) Mitochondrial Protein CMPK2 Regulates IFN Alpha-Enhanced Foam Cell Formation, Potentially Contributing to Premature Athero-sclerosis in SLE. Arthritis Research & Therapy, 23, Article No. 120. https://doi.org/10.1186/s13075-021-02470-6
|
[18]
|
Casey, K.A., Smith, M.A., Sinibaldi, D., et al. (2021) Modula-tion of Cardiometabolic Disease Markers by Type I Interferon Inhibition in Systemic Lupus Erythematosus. Arthritis & Rheumatology, 73, 459-471.
https://doi.org/10.1002/art.41518
|
[19]
|
Fayed, A., El Menyawi, M.M., Ghanema, M., et al. (2020) Measurement of Serum Interferon Alpha in Egyptian Patients with Systemic Lupus Erythematosus and Evaluation of Its Effect on Disease Activity: A Case-Control Study. Reumatismo, 72, 145-153. https://doi.org/10.4081/reumatismo.2020.1308
|
[20]
|
Zhang, W., Borcherding, N. and Kolb, R. (2020) IL-1 Signal-ing in Tumor Microenvironment. In: Birbrair, A., Ed., Tumor Microenvironment, Springer, Berlin, 1-23. https://doi.org/10.1007/978-3-030-38315-2_1
|
[21]
|
Zhou, L. and Todorovic, V. (2021) Interleukin-36: Structure, Signaling and Function. In: Atassi, M.Z., Ed., Protein Reviews, Springer, Berlin, 191-210. https://doi.org/10.1007/5584_2020_488
|
[22]
|
Duarte, A.L., Dantas, A.T., de Ataíde Mariz, H., et al. (2013) De-creased Serum Interleukin 27 in Brazilian Systemic Lupus Erythematosus Patients. Molecular Biology Reports, 40, 4889-4892. https://doi.org/10.1007/s11033-013-2588-1
|
[23]
|
Ryu, H. and Chung, Y. (2018) Dyslipidemia Pro-motes Germinal Center Reactions via IL-27. BMB Reports, 51, 371-372.
https://doi.org/10.5483/BMBRep.2018.51.8.171
|
[24]
|
Liu, Q., Fan, J., Bai, J., et al. (2018) IL-34 Promotes Foam Cell Formation by Enhancing CD36 Expression through p38 MAPK Pathway. Scientific Reports, 8, Article No. 17347. https://doi.org/10.1038/s41598-018-35485-2
|
[25]
|
Marczynski, P., Meineck, M., Xia, N., et al. (2021) Vascular In-flammation and Dysfunction in Lupus-Prone Mice-IL-6 as Mediator of Disease Initiation. International Journal of Mo-lecular Sciences, 22, Article No. 2291.
https://doi.org/10.3390/ijms22052291
|
[26]
|
El-Banna, H.S., El Khouly, R.M. and Gado, S.E. (2020) Elevated Se-rum Interleukin-34 Level in Juvenile Systemic Lupus Erythematosus and Disease Activity. Clinical Rheumatology, 39, 1627-1632.
https://doi.org/10.1007/s10067-019-04899-2
|
[27]
|
Wu, Y.R., Hsing, C.H., Chiu, C.J., et al. (2022) Roles of IL-1 and IL-10 Family Cytokines in the Progression of Systemic Lupus Erythematosus: Friends or Foes? IUBMB Life, 74, 143-156. https://doi.org/10.1002/iub.2568
|
[28]
|
Mohammadi, S., Ebadpour, M.R., Sedighi, S., et al. (2017) Gluco-corticoid-Induced Leucine Zipper Expression Is Associated with Response to Treatment and Immunoregulation in Sys-temic Lupus Erythematosus. Clinical Rheumatology, 36, 1765-1772. https://doi.org/10.1007/s10067-017-3711-9
|
[29]
|
Yamamoto, E.A., Nguyen, J.K., Liu, J., et al. (2020) Low Levels of Vitamin D Promote Memory B Cells in Lupus. Nutrients, 12, Article No. 291. https://doi.org/10.3390/nu12020291
|
[30]
|
Mellor-Pita, S., Tutor-Ureta, P., Rosado, S., et al. (2019) Calcium and Vitamin D Supplement Intake May Increase Arterial Stiffness in Systemic Lupus Erythematosus Patients. Clinical Rheumatology, 38, 1177-1186.
https://doi.org/10.1007/s10067-018-04416-x
|
[31]
|
Tabra, S., Abdelnabi, H.H., Darwish, N., et al. (2020) Juvenile Lupus and Serum Vitamin D Levels: A Cross-Sectional Study. Lupus, 29, 1752-1758. https://doi.org/10.1177/0961203320957721
|
[32]
|
Lee, T.W., Kao, Y.H., Chen, Y.J., et al. (2019) Therapeutic Po-tential of Vitamin D in AGE/RAGE-Related Cardiovascular Diseases. Cellular and Molecular Life Sciences, 76, 4103-4115. https://doi.org/10.1007/s00018-019-03204-3
|
[33]
|
Reynolds, J.A., Haque, S., Williamson, K., et al. (2016) Vitamin D Improves Endothelial Dysfunction and Restores Myeloid Angiogenic Cell Function via Reduced CXCL-10 Expression in Systemic Lupus Erythematosus. Scientific Reports, 6, Article No. 22341. https://doi.org/10.1038/srep22341
|
[34]
|
Oz, F., Cizgici, A.Y., Oflaz, H., et al. (2013) Impact of Vitamin D Insuffi-ciency on the Epicardial Coronary Flow Velocity and Endothelial Function. Coronary Artery Disease, 24, 392-397.
https://doi.org/10.1097/MCA.0b013e328362b2c8
|
[35]
|
Islam, M.A., Shahad SaifAlam, S.S. and PrzemyslawHas-san, R. (2019) Vitamin D Status in Patients with Systemic Lupus Erythematosus (SLE): A Systematic Review and Me-ta-Analysis. Autoimmunity Reviews, 18, Article ID: 102392.
https://doi.org/10.1016/j.autrev.2019.102392
|
[36]
|
Tselios, K., Koumaras, C., Gladman, D.D., et al. (2016) Dyslipidemia in Systemic Lupus Erythematosus: Just Another Comorbidity? Seminars in Arthritis and Rheumatism, 45, 604-610. https://doi.org/10.1016/j.semarthrit.2015.10.010
|
[37]
|
Zhou, B., Xia, Y. and She, J. (2020) Dysregulated Serum Lipid Profile and Its Correlation to Disease Activity in Young Female Adults Diagnosed with Systemic Lupus Er-ythematosus: A Cross-Sectional Study. Lipids in Health and Disease, 19, Article No. 40. https://doi.org/10.1186/s12944-020-01232-8
|
[38]
|
Ronda, N., Favari, E., Borghi, M.O., et al. (2014) Impaired Se-rum Cholesterol Efflux Capacity in Rheumatoid Arthritis and Systemic Lupus Erythematosus. Annals of Rheumatic Dis-eases, 73, 609-615.
https://doi.org/10.1136/annrheumdis-2012-202914
|
[39]
|
Olusi, S.O. and George, S. (2011) Prevalence of LDL Atherogenic Phenotype in Patients with Systemic Lupus Erythematosus. Vascular Health and Risk Management, 7, 75-80. https://doi.org/10.2147/VHRM.S17015
|
[40]
|
Kim, S.Y., Yu, M., Morin, E.E., et al. (2020) High-Density Lipoprotein in Lupus: Disease Biomarkers and Potential Therapeutic Strategy. Arthritis & Rheumatology, 72, 20-30. https://doi.org/10.1002/art.41059
|
[41]
|
Kotur-Stevuljević, J., Vekić, J., Stefanović, A., et al. (2020) Paraoxonase 1 and Atherosclerosis-Related Diseases. Bio- factors, 46, 193-205. https://doi.org/10.1002/biof.1549
|
[42]
|
Cochran, B.J., Ong, K.L., Manandhar, B., et al. (2021) APOA1: A Protein with Multiple Therapeutic Functions. Current Athero-sclerosis Reports, 23, Article No. 11. https://doi.org/10.1007/s11883-021-00906-7
|
[43]
|
Hevia, A., Milani, C., Lopez, P., et al. (2014) Intestinal Dysbiosis Associated with Systemic Lupus Erythematosus. mBio, 5, e01548-14. https://doi.org/10.1128/mBio.01548-14
|
[44]
|
Guo, M., Wang, H., Xu, S., et al. (2020) Alteration in Gut Microbiota Is Associated with Dysregulation of Cytokines and Glucocorticoid Therapy in Systemic Lupus Erythematosus. Gut Microbes, 11, 1758-1773.
https://doi.org/10.1080/19490976.2020.1768644
|
[45]
|
Li, Y., Wang, H.F., Li, X., et al. (2019) Disordered Intestinal Microbes Are Associated with the Activity of Systemic Lupus Erythematosus. Clinical Science (London), 133, 821-838. https://doi.org/10.1042/CS20180841
|
[46]
|
Brown, E.M., Kenny, D.J. and Xavier, R.J. (2019) Gut Microbiota Reg-ulation of T Cells during Inflammation and Autoimmunity. Annual Review of Immunology, 37, 599-624. https://doi.org/10.1146/annurev-immunol-042718-041841
|
[47]
|
Ruff, W.E., Dehner, C., Kim, W.J., et al. (2019) Pathogenic Autoreactive T and B Cells Cross-React with Mimotopes Expressed by a Common Human Gut Commensal to Trigger Autoimmunity. Cell Host & Microbe, 26, 100-113.e8.
https://doi.org/10.1016/j.chom.2019.05.003
|
[48]
|
Kasselman, L.J., Vernice, N.A., DeLeon, J., et al. (2018) The Gut Microbiome and Elevated Cardiovascular Risk in Obesity and Autoimmunity. Atherosclerosis, 271, 203-213. https://doi.org/10.1016/j.atherosclerosis.2018.02.036
|
[49]
|
Yoshida, N., Emoto, T., Yamashita, T., et al. (2018) Bacteroides vulgatus and Bacteroides dorei Reduce Gut Microbial Lipopolysaccharide Production and Inhibit Athero-sclerosis. Circulation, 138, 2486-2498.
https://doi.org/10.1161/CIRCULATIONAHA.118.033714
|